Search clinical trials for: autologous anti-MART-1 F5 T-cell receptor

Total 388 results

Cellular Biomedicine Group Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

China
Cellular Biomedicine Group Ltd.
Shanghai Tongji Hospital, Tongji University School of Medicine

Unknown

Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

Refractory or Relapsed Non-Hodgkin Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Melanoma (Skin)

United States
Chinese PLA General Hospital

Recruiting

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Anterogen Co., Ltd.

Terminated

Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211) (ANTG)

Perianal Fistula | Primary; Complex

Korea, Republic of
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Guy's and St Thomas' NHS Foundation Trust
King's College London

Completed

Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients (ThRIL)

End-stage Liver Disease

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
University of Alberta
Alberta Cancer Foundation; Canadian Cancer Trials Group

Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)

Relapsed Non Hodgkin Lymphoma | Relapsed Pediatric ALL | Relapsed Adult ALL

Canada
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Completed

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

B-cell Lymphoma

China
Nantes University Hospital

Completed

Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones

Immunotherapy

France
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Beijing Tsinghua Chang Gung Hospital
Beijing DCTY® Biotech Co.,Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Recurrent Glioblastoma
Rapa Therapeutics LLC
Medical College of Wisconsin

Recruiting

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Relapsed, Refractory Multiple Myeloma

United States
Peking University
Marino Biotechnology Co., Ltd.

Unknown

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

B-cell Lymphoma

China
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Christian Hinrichs
National Cancer Institute (NCI)

Not yet recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical Cancer | HPV-Related Malignancy | Vulvar Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Associated Cervical Carcinoma | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
Ottawa Hospital Research Institute

Recruiting

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

Canada
National Cancer Institute (NCI)

Completed

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Melanoma

United States
Sara V. Latorre
Instituto de Salud Carlos III; Fondos ARI (Assistencia Recerca Intensiva); Fondo...

Active, not recruiting

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

Relapsed/Refractory Multiple Myeloma

Spain
Fundacion Clinic per a la Recerca Biomedica

Not yet recruiting

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma (CARTD-BG-1)

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

Spain
Miltenyi Biomedicine GmbH
ICON plc

Active, not recruiting

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

B-cell Non Hodgkin Lymphoma

Germany
Peking University People's Hospital
Cellular Biomedicine Group Ltd.

Unknown

C-CAR011 Treatment in Subjects With ALL After HSCT

Acute Lymphoblastic Leukemia(ALL)

China
Guy's and St Thomas' NHS Foundation Trust
King's College London

Completed

The ONE Study UK Treg Trial (ONETreg1)

End-stage Renal Failure

United Kingdom
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Terminated

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

Pemphigus Vulgaris | Pemphigus Foliaceus

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Hangzhou Cancer Hospital
Anhui Kedgene Biotechnology Co.,Ltd

Completed

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Esophageal Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Imcyse SA

Terminated

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis (SCLEROLYM)

Multiple Sclerosis, Relapsing-Remitting

Belgium
National Cancer Institute (NCI)

Terminated

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

Papillomavirus Infections | Oropharyngeal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer

Uterine Cervical Neoplasms

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Completed

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy (HXTC)

HIV

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Xinqiao Hospital of Chongqing
TCRCure Biopharma Ltd.

Not yet recruiting

Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer

Ovarian Cancer | Endometrial Cancer
Roger Williams Medical Center

Terminated

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

Neoplasms | Metastatic Cancer | Solid Tumors | Tumors

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
Affiliated Hospital to Academy of Military Medical...

Unknown

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Adult Acute Myeloid Leukemia

China
National Cancer Institute (NCI)

Terminated

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Melanoma | Skin Cancer

United States
National Cancer Institute (NCI)

Terminated

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

Prostatic Neoplasms | Prostate Cancer

United States
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
National Cancer Institute (NCI)
Georgetown University; Hackensack Meridian Health

Terminated

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell | Myelomatosis

United States
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Affini-T Therapeutics, Inc.

Active, not recruiting

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Other Skin

United States
Prof. Dr. Petra Reinke

Completed

The ONE Study nTreg Trial (ONEnTreg13) (ONEnTreg13)

Immunosuppressive Treatment of Living-donor Renal Transplantation

Germany
Emory University
National Cancer Institute (NCI); Novartis; Secura Bio, Inc.

Recruiting

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States

Search clinical trials for: autologous anti-MART-1 F5 T-cell receptor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations